Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up

Beam Therapeutics receives a Buy rating, driven by promising data across AATD, GSDIa, and SCD, and robust funding. BEAM's risto-cel SCD therapy shows strong efficacy but faces market skepticism due to challenging treatment regimens and competition. The company's in-vivo gene editing pipeline, especially BEAM-302 in AATD, is viewed as the primary value driver amid industry doubts.